Biomarkers for smoking cessation

K. J. Bough; C. Lerman; J. E. Rose; F. J. McClernon; P. J. Kenny; R. F. Tyndale; S. P. David; E. A. Stein; G. R. Uhl; D. V. Conti; C. Green; S. Amur

doi:10.1038/clpt.2013.57

Biomarkers for smoking cessation

K. J. Bough, C. Lerman, J. E. Rose, F. J. McClernon, P. J. Kenny, R. F. Tyndale, S. P. David, E. A. Stein, G. R. Uhl, D. V. Conti, C. Green, S. Amur

Research output: Contribution to journal › Article › peer-review

49 Scopus citations

Abstract

One way to enhance therapeutic development is through the identification and development of evaluative tools such as biomarkers. This review focuses on putative diagnostic, pharmacodynamic, and predictive biomarkers for smoking cessation. These types of biomarkers may be used to more accurately diagnose a disease, personalize treatment, identify novel targets for drug discovery, and enhance the efficiency of drug development. Promising biomarkers are presented across a range of approaches including metabolism, genetics, and neuroimaging. A preclinical viewpoint is also offered, as are analytical considerations and a regulatory perspective summarizing a pathway toward biomarker qualification.

Original language	English
Pages (from-to)	526-538
Number of pages	13
Journal	Clinical Pharmacology and Therapeutics
Volume	93
Issue number	6
DOIs	https://doi.org/10.1038/clpt.2013.57
State	Published - Jun 2013
Externally published	Yes

Access to Document

10.1038/clpt.2013.57

Cite this

@article{12d0debb763a4b1b94c60c5e522fe923,

title = "Biomarkers for smoking cessation",

abstract = "One way to enhance therapeutic development is through the identification and development of evaluative tools such as biomarkers. This review focuses on putative diagnostic, pharmacodynamic, and predictive biomarkers for smoking cessation. These types of biomarkers may be used to more accurately diagnose a disease, personalize treatment, identify novel targets for drug discovery, and enhance the efficiency of drug development. Promising biomarkers are presented across a range of approaches including metabolism, genetics, and neuroimaging. A preclinical viewpoint is also offered, as are analytical considerations and a regulatory perspective summarizing a pathway toward biomarker qualification.",

author = "Bough, {K. J.} and C. Lerman and Rose, {J. E.} and McClernon, {F. J.} and Kenny, {P. J.} and Tyndale, {R. F.} and David, {S. P.} and Stein, {E. A.} and Uhl, {G. R.} and Conti, {D. V.} and C. Green and S. Amur",

year = "2013",

month = jun,

doi = "10.1038/clpt.2013.57",

language = "English",

volume = "93",

pages = "526--538",

journal = "Clinical Pharmacology and Therapeutics",

issn = "0009-9236",

publisher = "Wiley-Blackwell",

number = "6",

}

TY - JOUR

T1 - Biomarkers for smoking cessation

AU - Bough, K. J.

AU - Lerman, C.

AU - Rose, J. E.

AU - McClernon, F. J.

AU - Kenny, P. J.

AU - Tyndale, R. F.

AU - David, S. P.

AU - Stein, E. A.

AU - Uhl, G. R.

AU - Conti, D. V.

AU - Green, C.

AU - Amur, S.

PY - 2013/6

Y1 - 2013/6

N2 - One way to enhance therapeutic development is through the identification and development of evaluative tools such as biomarkers. This review focuses on putative diagnostic, pharmacodynamic, and predictive biomarkers for smoking cessation. These types of biomarkers may be used to more accurately diagnose a disease, personalize treatment, identify novel targets for drug discovery, and enhance the efficiency of drug development. Promising biomarkers are presented across a range of approaches including metabolism, genetics, and neuroimaging. A preclinical viewpoint is also offered, as are analytical considerations and a regulatory perspective summarizing a pathway toward biomarker qualification.

AB - One way to enhance therapeutic development is through the identification and development of evaluative tools such as biomarkers. This review focuses on putative diagnostic, pharmacodynamic, and predictive biomarkers for smoking cessation. These types of biomarkers may be used to more accurately diagnose a disease, personalize treatment, identify novel targets for drug discovery, and enhance the efficiency of drug development. Promising biomarkers are presented across a range of approaches including metabolism, genetics, and neuroimaging. A preclinical viewpoint is also offered, as are analytical considerations and a regulatory perspective summarizing a pathway toward biomarker qualification.

UR - http://www.scopus.com/inward/record.url?scp=84878215517&partnerID=8YFLogxK

U2 - 10.1038/clpt.2013.57

DO - 10.1038/clpt.2013.57

M3 - Article

C2 - 23588313

AN - SCOPUS:84878215517

SN - 0009-9236

VL - 93

SP - 526

EP - 538

JO - Clinical Pharmacology and Therapeutics

JF - Clinical Pharmacology and Therapeutics

IS - 6

ER -

Biomarkers for smoking cessation

Abstract

Access to Document

Fingerprint

Cite this